Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
18/05/2026 19:33
BOSTON, May 18 (Reuters) - A U.S. jury on Monday found that Takeda Pharmaceutical 4502.T caused pharmacies, insurers, retailers and others to sustain about $885 million in damages delaying the release of a generic version of its anti-constipation drug Amitiza through an anticompetitive scheme. (Reporting by Nate Raymond in Boston; Editing by Chris Reese) ((Nate.Raymond@thomsonreuters.com; 347-243-6917; Reuters Messaging: nate.raymond.thomsonreuters.com@reuters.net))
Recent news on Takeda Pharmaceutical
See all newsTakeda launches sleep disorder pill in the US after DEA clearance removes final hurdle (updated)
Brief: Takeda's Orzeyful Available In U.S. By Prescription To Treat Narcolepsy Type 1 In Adults
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
Takeda Pharmaceutical Company Limited reports results for the quarter ended September 30 - Earnings Summary
Table: Takeda Pharmaceutical Company Limited -6-MTH group results (IFRS)